N4 Pharma Plc (AIM:N4P)
London · Delayed Price · Currency is GBP · Price in GBX 0.3750
+0.0225 (6.00%)
Jul 18, 2025, 4:35 PM GMT+1
N4 Pharma Company Description
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom.
It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene.
The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring.
N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
N4 Pharma Plc
| Country | United Kingdom |
| Founded | 1979 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Nigel Theobald |
Contact Details
Address: 8 Bishopsgate London, EC2N 4BQ United Kingdom | |
| Website | n4pharma.com |
Stock Details
| Ticker Symbol | N4P |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BYW8QM32 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Nigel Theobald | Chief Executive Officer |